Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Vir Biotechnology (VIR) will host a conference call on November 4, 2026, to discuss its third-quarter financial results. The call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT and will include a ...

SPDR SERIES TRUST-State Street SPDR Portfolio S&P 600 Small Cap ETF 1.16M Sep 30, 2026 0.69% 12,289,326 ...

Vir Biotechnology generated $68.6M in revenue in FY2025, retaining a 100.0% gross margin, operating income reached -$479.3M, and net income was -$438.0M. Diluted earnings per share stood at -$3.16.

Vir Biotechnology is now a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 program. Gilead’s bulevirtide launch is expanding hepatitis delta diagnosis, ...

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.560 between high and low, or 5.58%. For the ...

2027 Mar 28 14 nights, one-way from Vienna to Constanta Vienna $6795 2027 Apr 11 14 nights, one-way from Constanta to Vienna Constanta $5395 2027 Apr 25 14 nights, one-way from Vienna to Constanta ...